Related Experiment Video

Updated: Mar 20, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.9K

Splenectomy may not influence glutathione metabolism in children with beta-thalassaemia major

Mahdi Garelnabi, Pushpa Paradhan

    Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology
    |June 7, 2016
    PubMed

    Insights

    Glutathione metabolism is significantly altered in beta-thalassaemia major. Splenectomy does not appear to influence these glutathione changes in children with beta-thalassaemia major.

    Area of Science:

    • Biochemistry
    • Hematology
    • Pediatrics

    Background:

    • Beta-thalassaemia major is a severe inherited blood disorder.
    • Glutathione (GSH) and its related enzymes play crucial roles in cellular defense against oxidative stress.
    • Understanding these metabolic pathways is vital for managing the disease.

    Purpose of the Study:

    • To evaluate glutathione and related enzyme levels in children with beta-thalassaemia major.
    • To investigate the impact of splenectomy on glutathione metabolism in these patients.

    Main Methods:

    • Erythrocyte levels of reduced glutathione, glutathione peroxidase, glutathione reductase, and glucose-6-phosphate dehydrogenase were measured.
    • Three groups were studied: healthy controls, beta-thalassaemia major patients with intact spleen, and splenectomized beta-thalassaemia major patients.

    Main Results:

    • Thalassaemic patients showed significantly increased glutathione and glutathione reductase levels (p<0.001, p<0.05 respectively).
    • Glutathione peroxidase levels were significantly decreased in thalassaemic patients (p<0.005).
    • While similar patterns were observed in splenectomized patients, differences between splenectomized and non-splenectomized groups were not statistically significant.

    Conclusions:

    • Glutathione and its redox enzymes are significantly disturbed in beta-thalassaemia major.
    • Splenectomy does not appear to influence glutathione metabolism in children with beta-thalassaemia major.

    More Related Videos

    Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

    Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

    Published on: March 14, 2017

    20.6K
    A Mouse Model of Vascularized Heterotopic Spleen Transplantation for Studying Spleen Cell Biology and Transplant Immunity08:04

    A Mouse Model of Vascularized Heterotopic Spleen Transplantation for Studying Spleen Cell Biology and Transplant Immunity

    Published on: June 11, 2019

    17.2K

    Related Concept Videos

    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    313
    Bone Marrow Sampling and Transplants01:22

    Bone Marrow Sampling and Transplants

    Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
    The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
    2.2K
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
    248
    Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

    Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

    Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
    Several distinctive characteristics distinguish glutathione conjugation from other phase II...
    1.2K
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    324
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    327